Pharmaceutical company Dr Reddy's Laboratories Ltd (BSE:500124)(NSE:DRREDDY) (NYSE:RDY) on Wednesday announced the availability of Bortezomib for Injection 3.5 mg/vial for intravenous use only in the US cancer market.
The company added that the Bortezomib for Injection 3.5 mg/vial has been approved by the US Food and Drug Administration (USFDA) via a 505(b)(2) new drug application (NDA) pathway.
In addition, the US FDA has approved the company's Bortezomib for Injection 3.5 mg/vial for the treatment of adult patients with multiple myeloma as well as for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
Dr Reddy's Laboratories stated that it is committed to providing affordable and innovative medicines for healthier lives. It operates through three businesses: Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval